The first patient has been enrolled in the PROSTATE-IQ trial of ArteraAI, a multimodal artificial intelligence biomarker test ...

ARC101, a potential best-in-class T-cell engager that targets solid tumors expressing CLDN6, is being assessed in a ...

This review discusses the current state of multicancer early detection tests, the role of machine learning in their ...

During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...

In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in ...

An expert discusses strategies for monitoring response to treatment, including observation, Epstein-Barr virus (EBV) titers, ...

During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...

Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

A panelist discusses how treatment strategies for recurrent nasopharyngeal carcinoma (NPC) have evolved, with the updated ...

An expert discusses emerging developments in the use of systemic immunotherapy for recurrent/metastatic nasopharyngeal carcinoma (NPC) from the perspective of a radiation oncologist, highlighting how ...

An expert discusses how advances in JAK V617F monitoring have improved the assessment of disease status and guided treatment decisions and how risk assessment tools have transformed the ability to ...

Jacob E. Berchuck, MD, highlights challenges in adopting liquid biopsy for PSMA expression and its potential to revolutionize precision medicine in prostate cancer.